SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-040608
Filing Date
2024-03-28
Accepted
2024-03-28 17:08:25
Documents
16
Period of Report
2024-03-28
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2410082d1_8k.htm   iXBRL 8-K 35687
2 EXHIBIT 3-1 tm2410082d1_ex3-1.htm EX-3.1 13462
3 EXHIBIT 99.1 tm2410082d1_ex99-1.htm EX-99.1 11829
  Complete submission text file 0001104659-24-040608.txt   290939

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20240328.xsd EX-101.SCH 3245
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20240328_def.xml EX-101.DEF 26897
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20240328_lab.xml EX-101.LAB 36508
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20240328_pre.xml EX-101.PRE 25521
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2410082d1_8k_htm.xml XML 5430
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 24800251
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)